Maini A, Morse P D, Wang C Y, Jones R F, Haas G P
Department of Urology, State University of New York, Syracuse 13210, USA.
Anticancer Res. 1997 Sep-Oct;17(5B):3803-8.
Cytokines, the pleiotropic immune regulatory proteins, are involved in the regulation of cell growth, differentiation and functional activation. Novel cytokines have been enumerated in rapid succession and entered the clinical arena. IL-2 is well recognized for its antitumor effects and is accepted therapy for numerous malignancies. IL-l and IL-11 are important as thrombopoetic factors while IL-6 has been introduced in clinical trials as a platelet growth factor and as an antitumor agent. IL-4 has shown growth inhibitory effects against many solid tumor cell lines in vitro, but its direct effect on human tumors in vivo remains to be explored. IL-7 may be an important addition to the current strategies of adoptive immunotherapy. IL-12 plays a fundamental role in activating antitumor cellular immunity. When given with tumor associated antigens, IL-12 has proven effective against many forms of metastatic solid tumors. Immunotoxins appear to be promising, though the antigenicity of the molecule and antibody development aspects remain to be resolved. The current review will focus on the clinical use of novel cytokines for the treatment of cancer.
细胞因子是具有多效性的免疫调节蛋白，参与细胞生长、分化和功能激活的调节。新型细胞因子相继被发现并进入临床应用。白细胞介素-2（IL-2）因其抗肿瘤作用而广为人知，是多种恶性肿瘤的公认治疗药物。白细胞介素-1（IL-1）和白细胞介素-11（IL-11）作为血小板生成因子很重要，而白细胞介素-6（IL-6）已在临床试验中作为血小板生长因子和抗肿瘤药物引入。白细胞介素-4（IL-4）在体外对许多实体瘤细胞系显示出生长抑制作用，但其对体内人类肿瘤的直接作用仍有待探索。白细胞介素-7（IL-7）可能是当前过继性免疫治疗策略的重要补充。白细胞介素-12（IL-12）在激活抗肿瘤细胞免疫中起基本作用。与肿瘤相关抗原联合使用时，IL-12已被证明对多种形式的转移性实体瘤有效。免疫毒素似乎很有前景，尽管分子的抗原性和抗体开发方面仍有待解决。本综述将聚焦新型细胞因子在癌症治疗中的临床应用。
